EWMA

Fertram Sigurjonsson, Founder and CEO of Medical-Fish-Skin Company Kerecis, Receives the EWMA President’s Wound Care Entrepreneur of the Year Award

Retrieved on: 
星期五, 五月 3, 2024
Biotechnology, Pharmaceutical, Alternative Medicine, Medical Supplies, General Health, Health, Medical Devices, Other Health, European Wound Management Association, Multimedia, Dicarboxylic acid, Sigurjónsson, Trauma, Entrepreneurship, EWMA, Patient, Learning, Burns, Skin, Nursing

The European Wound Management Association (EWMA) presented Fertram Sigurjonsson , founder and CEO of the medical-fish-skin company Kerecis, with the President’s Wound Care Entrepreneur of the Year Award.

Key Points: 
  • The European Wound Management Association (EWMA) presented Fertram Sigurjonsson , founder and CEO of the medical-fish-skin company Kerecis, with the President’s Wound Care Entrepreneur of the Year Award.
  • The award was announced at the annual EWMA Innovation Forum .
  • View the full release here: https://www.businesswire.com/news/home/20240503572390/en/
    Fertram Sigurjonsson, Founder and CEO of Kerecis, receives the President’s Wound Care Entrepreneur of the Year Award from Kirsi Isoherranen, President of European Wound Care Association (EWMA).
  • We will continue pushing science's boundaries to meet their needs and advance medical treatment,” said Sigurjonsson.

NOVEL OMEZA® OCM™ WOUND HEALING PLATFORM COMBINED WITH OFFLOADING IN PATIENTS WITH DIABETIC FOOT ULCERS DEMONSTRATED DRAMATIC HEALING RATES WITHIN 12 WEEKS OR LESS

Retrieved on: 
星期五, 五月 3, 2024
Collagen, ProMedica, Mortality, University, Patient, Debridement, Diabetes, DFU, Conference, Foot, Diabetic foot ulcer, Peptide, PAR, European Wound Management Association, Wound healing, Clinical trial, EWMA, Plastic, Disease, Pharmaceutical industry

"We're extremely encouraged by the final results of our clinical trial evaluating Omeza®'s OCM™ platform, which showed significant healing—and in over half the cases, complete closure—of patients' diabetic wounds in twelve weeks or less.

Key Points: 
  • "We're extremely encouraged by the final results of our clinical trial evaluating Omeza®'s OCM™ platform, which showed significant healing—and in over half the cases, complete closure—of patients' diabetic wounds in twelve weeks or less.
  • Patients also reduced or eliminated weight bearing on the affected foot, known as offloading, to support healing.
  • A control group received current standards of wound care, including offloading, debridement, collagen, hypochlorite solution, and/or wound dressings containing silver alginate.
  • Five patients had DFUs that were greater than 12 months old, and 3 of those patients had 100% PAR.

MolecuLight Featured in 11 Presentations and Posters at European Wound Management Association (EWMA) 2024 Annual Conference

Retrieved on: 
星期三, 五月 1, 2024
Enhanced, Health equity, Publication, DX, Collection, Health Canada, Conference, Research, Pyoderma, Workflow, Detection, Patient, European Wound Management Association, EWMA, Quality of life, Medical imaging

TORONTO and LONDON, May 1, 2024 /PRNewswire/ - MolecuLight Inc. , the leader in point-of-care digital wound measurement and real-time bacterial detection through fluorescence imaging, announces that its MolecuLight wound imaging platform is being prominently featured in several presentations and posters at the European Wound Management Association (EWMA) 2024 Annual Conference, being held from May 1 - 3, 2024 in London, United Kingdom.

Key Points: 
  • TORONTO and LONDON, May 1, 2024 /PRNewswire/ - MolecuLight Inc. , the leader in point-of-care digital wound measurement and real-time bacterial detection through fluorescence imaging, announces that its MolecuLight wound imaging platform is being prominently featured in several presentations and posters at the European Wound Management Association (EWMA) 2024 Annual Conference, being held from May 1 - 3, 2024 in London, United Kingdom.
  • The annual EWMA meeting is the largest wound care conference in Europe and one of the largest events globally for wound care professionals.
  • "The impressive collection of at least 11 talks and posters from multiple and diverse facilities globally shows how the MolecuLight imaging device is becoming a new standard-of-care in this specialty.
  • A selection of the clinical posters and presentation featuring the MolecuLight i:X and DX from European Wound Management Association (EWMA) 2024 Annual Conference are as follows:
    (a)  Select Clinical Presentations and Workshops citing the MolecuLight point-of-care devices include:
    Presentation on MolecuLight by Dr. Jonathan Johnson
    Does bacterial fluorescence imaging improve chronic wound biofilm detection over standard clinical assessment and blotting?

MolecuLight Featured in 11 Presentations and Posters at European Wound Management Association (EWMA) 2024 Annual Conference

Retrieved on: 
星期三, 五月 1, 2024
Enhanced, Health equity, Publication, DX, Collection, Health Canada, Conference, Research, Pyoderma, Workflow, Detection, Patient, European Wound Management Association, EWMA, Quality of life, Medical imaging

TORONTO and LONDON, May 1, 2024 /PRNewswire/ -- MolecuLight Inc., the leader in point-of-care digital wound measurement and real-time bacterial detection through fluorescence imaging, announces that its MolecuLight wound imaging platform is being prominently featured in several presentations and posters at the European Wound Management Association (EWMA) 2024 Annual Conference, being held from May 1 - 3, 2024 in London, United Kingdom. The annual EWMA meeting is the largest wound care conference in Europe and one of the largest events globally for wound care professionals.

Key Points: 
  • TORONTO and LONDON, May 1, 2024 /PRNewswire/ -- MolecuLight Inc. , the leader in point-of-care digital wound measurement and real-time bacterial detection through fluorescence imaging, announces that its MolecuLight wound imaging platform is being prominently featured in several presentations and posters at the European Wound Management Association (EWMA) 2024 Annual Conference, being held from May 1 - 3, 2024 in London, United Kingdom.
  • The annual EWMA meeting is the largest wound care conference in Europe and one of the largest events globally for wound care professionals.
  • "The impressive collection of at least 11 talks and posters from multiple and diverse facilities globally shows how the MolecuLight imaging device is becoming a new standard-of-care in this specialty.
  • A selection of the clinical posters and presentation featuring the MolecuLight i:X and DX from European Wound Management Association (EWMA) 2024 Annual Conference are as follows:
    (a)  Select Clinical Presentations and Workshops citing the MolecuLight point-of-care devices include:
    Presentation on MolecuLight by Dr. Jonathan Johnson
    Does bacterial fluorescence imaging improve chronic wound biofilm detection over standard clinical assessment and blotting?

MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences

Retrieved on: 
星期四, 四月 25, 2024
Symposium, WHS, Patient, SAWC, Wound, European Wound Management Association, Wound healing, EWMA, Nursing

YAVNE, Israel, April 25, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, announced today that recent clinical data from EscharEx® Phase II studies will be presented throughout May 2024 at the largest, most prestigious annual meetings in the field of chronic wound care: the European Wound Management Association (EWMA), the Wound Healing Society (WHS), and the Symposium on Advanced Wound Care (SAWC).

Key Points: 
  • The oral presentations on EscharEx will include:
    Comparative data of EscharEx vs. SANTYL® that demonstrate EscharEx’s superiority over the current leading enzymatic debridement agent
    New analyses from the ChronEx phase II study, showing high correlation between wound bed preparation and wound healing
    These data indicate that EscharEx could substantially improve wound care for patients with debilitating chronic wounds, providing significant benefits over the current standard of care.
  • Additionally, the findings support the design and endpoints of the upcoming Phase III study, which is expected to begin in the second half of 2024.
  • "We are delighted to present the results of additional analyses from EscharEx Phase II studies in chronic hard-to-heal wounds, including the positive comparative data with SANTYL®, the current dominant standard of care for enzymatic debridement," said Dr. Robert J. Snyder, Chief Medical Officer of MediWound.
  • "With its robust efficacy, favorable safety profile, and multimodal mechanistic effects demonstrated in these Phase II studies, we believe that EscharEx can significantly advance wound care and has the potential to become a major player in the global wound care market."

Kerecis to Provide Multiple Updates on its Medical-Fish-Skin Technology at the European Wound Management Association Meeting

Retrieved on: 
星期三, 五月 1, 2024
Biotechnology, Surgery, Diabetes, Health, Medical Supplies, Use, Skin, Abstract, Excellence, Dicarboxylic acid, Cost, European Wound Management Association, Multimedia, Human, Complex, General surgery, EWMA, Fixation (psychology), NPWT, User experience, Dietary supplement

The company will also host a medical education event on the utilization of fish skin grafts on Wednesday, May 1.

Key Points: 
  • The company will also host a medical education event on the utilization of fish skin grafts on Wednesday, May 1.
  • Finally, Kerecis’ founder and CEO will summarize the company’s journey at the EWMA Innovation Forum Thursday, May 2.
  • Kerecis will be the subject of the following events at the conference:
    Intact Fish Skin for Chronic Wound Care – Dr. John Lantis, chair.
  • Thursday, May 2, 4 to 5 p.m. in the South Gallery Room 8-9-10
    Fish Skin for Wound Management: Are There Advantages?

MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

Retrieved on: 
星期四, 三月 21, 2024
Burn, Tax, Debridement, Patient, EWMA, Bank statement, Eschar, Investment, SAWC, Therapy, Depreciation, European Commission, Phase, BCC, Research, Supplement, Wound, EMA, GMP, HERE, Safety, CMS, BLA, Eastern Time Zone, Food, Bromelain (pharmacology), WBP, Development, PMI, WHS, Adjustment, FDA, BMCI, Forecasting, Symposium, Incidence, BSV, Basal-cell carcinoma, Operating cost, European Wound Management Association, Table, Event, Medicare, Pharmaceutical industry

YAVNE, Israel, March 21, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • Revenue: Revenue for the fourth quarter 2023 was $5.3 million, compared to $11.6 million in the fourth quarter of 2022.
  • Research and development expenses in the fourth quarter 2023 were $1.8 million compared to $2.7 million in the fourth quarter of 2022.
  • Selling, general, and administrative expenses in the fourth quarter 2023 were $2.8 million, compared to $3.0 million in the fourth quarter of 2022.
  • Operating Results: Operating loss in the fourth quarter of 2023 was $3.9 million, compared to an operating profit of $2.1 million in the fourth quarter of 2022.

US monetary policy is more powerful in low economic growth regimes

Retrieved on: 
星期二, 四月 2, 2024
Tao, Research Papers in Economics, Excess, American Economic Journal, Doan, Policy, RT, Interpolation, Economic growth, Absorption, Business, E32, Low, Browning, European Economic Review, UST, NBER, Forecasting, Macroeconomics, European Economic Association, Journal of Monetary Economics, Journal of Applied Econometrics, TVAR, Oxford University Press, Time series, Economic Inquiry, Paper, Linearity, Joshua Angrist, Nobuhiro, Environment, Political economy, Journal of Financial Economics, Rated R, R2, Website, Emi, Energy economics, Probability, Medical classification, Eurozone, Sigismund, Quarterly Journal of Economics, Zero lower bound, History, Nature, Chapter, ZT, Journal of Political Economy, Bocconi University, OLS, Statistics, University of California, Irvine, PDF, Classification, ECB, XS, ITP, Impact, Estimation, DGP, Mark Thoma, Social science, Elsevier, JEL, Cambridge University Press, Real, M1, Research, Textbook, Private sector, FED, Credit, UTT, Literature, Federal Reserve, Knotek, Evelyn Regner, Table, European Central Bank, Chow, FRED, Monetary economics, Wald, Ben Bernanke, Premium, P500, BIS, EWMA, International Economic Review, Federal funds rate, Money, Treasury, C32, The Economic Journal, Federal Reserve Economic Data, Employment, Risk, FFR, Suggestion, FOMC, Monte Carlo method, Sigmoid, VAR, Database, Projection, Ascari, The Journal of Finance, Yield curve, United States Treasury security, Economy, Fed, Figure, NFCI, Financial economics, EXP, Freedom, Central bank, PCE, Monetary policy, American Economic Review, Exercise, Interest, Samuel, URR, Rigidity, Business cycle, XT, Landing slot, Chap, Daron Acemoglu, Markov, Blue chip, Kuttner, Response, Quarterly Journal, YT, Channel, GDP, Standard, Effect, Federal, Cost, Christian Social Union (UK), Journal of Econometrics, Comm, Mark Gertler, Use, Economic statistics, IW, Bank for International Settlements, Finance Secretary (India), UC, Bank, Reproduction, Section, News, Housing, Data, Food industry
Key Points: 

    MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study

    Retrieved on: 
    星期一, 二月 12, 2024
    Incidence, FDA, EWMA, Safety, Debridement, Wound, WBP, Patient, Symposium, WHS, Granulation tissue, Disease, SAWC, NSS, European Wound Management Association, Wound healing

    SANTYL is currently the market-leading enzymatic debridement product, with more than $360 million in estimated annual sales in the United States.

    Key Points: 
    • SANTYL is currently the market-leading enzymatic debridement product, with more than $360 million in estimated annual sales in the United States.
    • Ofer Gonen, CEO of MediWound said, “These head-to-head results position EscharEx to become the market leader in enzymatic agents for the treatment of chronic wounds.
    • All are achieved within a short time frame to facilitate early wound closure, a major benefit for patients suffering from chronic non-healing wounds.
    • The incidence of achieving WBP throughout the study was 78.3% (95% CI = 63.6-89.1) for EscharEx vs. 37.5% for SANTYL (95% CI=8.5-75.5); p=0.03.

    SANUWAVE Announces Q2 2023 Financial Results

    Retrieved on: 
    星期五, 八月 11, 2023
    Acceleration, Health, EWMA, Sale, Regenerative medicine, Traction, Symposium, Distribution, Wound healing, EDEN, FDA, Conference, Pharmaceutical industry, Clothing, Cryptocurrency, Internet service provider, Q3, Q2

    EDEN PRAIRIE, MN, Aug. 11, 2023 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (the “Company” or “SANUWAVE”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, today announced its 2nd quarter 2023 results.

    Key Points: 
    • EDEN PRAIRIE, MN, Aug. 11, 2023 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (the “Company” or “SANUWAVE”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, today announced its 2nd quarter 2023 results.
    • This growth falls within the previously provided guidance range of 15-25% for Q2 2023.
    • 49 UltraMist® systems were sold in Q2 2023, up from 28 in Q1 of this year.
    • SANUWAVE its constrained inventory supply will improve materially and enable an acceleration of revenue growth in Q4 2023.